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Infectious diseases caused by viruses are among the most vexing medical issues that we are yet to solve,
even with billions of dollars being spent on drugs and vaccines to combat and prevent such infections.
Finding a cure or vaccine for some of the most common or the most deadly viruses such as the
inﬂuenza or the Ebola virus has been a daunting task due to their constant mutation and adaptation to
our attempts. Existing therapeutics that lose their eﬀectiveness with time due to mutations have
brought about the need to consider alternative treatment approaches. To cater to the ever-increasing
demand for new antiviral strategies, a novel approach of using high aﬃnity polymeric receptors
prepared by a molecular imprinting technique to “catch” viruses is presented. After three hours of
mixing with the template virus, a very signiﬁcant reduction in infectivity titers was observed with the
virus imprinted particles. The virucidal action of the imprinted particles was rapid, dose dependent on
virus and polymer concentration and occurred due to speciﬁc adsorption. The fabricated nanoparticles
displayed remarkable positive anti-viral results that signiﬁcantly hindered viral infections as compared to
the controls. This work thus successfully demonstrates the application of miniemulsion polymerization
to surface imprinting of viruses and the novel application of such imprinted materials in infectious
disease treatment. The ﬁndings represent a signiﬁcant breakthrough in the ﬁeld of molecular imprinting
and antiviral therapy and we anticipate this work to be a starting point for path-breaking research in
the near future.Viruses are pathogens that have the capability to infect all types
of organisms. In particular for humans, viral infections and
diseases such as AIDS, hepatitis, dengue and inuenza pose
signicant social and economic problems in all nations. At
present, the most common routes of controlling viral diseases
are through vaccinations and anti-virals. Current antiviral drugs
include channel and transcription blocking compounds,
immunoglobulins, nucleoside analogs, polymerase, fusion,
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Chemistry 2013targeting diﬀerent stages of viral infection.1 On the other hand,
viral vaccines have been very successful in preventing infec-
tions, for example, against smallpox, polio and measles,
producing an enormous positive impact on world health over
the last 50 years. Due to the increasing threat of pandemics and
mortality rates, the need for an eﬀective antiviral therapy is of
great urgency. In this regard, we propose polymeric virus
catchers prepared by molecular imprinting as a cheaper, faster,
more stable, and safer mode of therapy.
Molecular imprinting is a technique that can create tailor-
made articial materials that possess comparable molecular
recognition and binding capabilities as with natural biomole-
cules like antibodies. It involves the creation of three dimen-
sional highly specic binding sites in a synthetic matrix (‘the
lock’) that are complementary to the size, shape and functional
group orientation of the ‘substrate’ molecule (‘the key’). In
contrast to natural receptors, these synthetic materials,
commonly made of polymers, are mechanically and chemically
more robust, reusable and easily reproducible on a large scale.
Thus, molecularly imprinted polymers (MIPs) have been
extensively used as substitutes for antibodies or enzymes in a
wide range of technologies such as separation and purication,2
sensing,3 catalysis4 and drug delivery.5 In the past few decades,
the imprinting technique has been applied from smallJ. Mater. Chem. B, 2013, 1, 2031–2037 | 2031





















































































View Article Onlinemolecular templates6 to larger biomolecules like proteins7–10
and even whole cells.11 For large particles like viruses, many
groups have focused on imprinting on two-dimensional (2D)
surfaces mainly for virus detection.12 In addition to using the
entire viral protein as a template, an epitope (a short amino acid
sequence) approach has also been employed.13 For example, a
molecularly imprinted lm was prepared in the presence of an
epitope of NS1 (nonstructural) protein, excreted from infected
cells into the blood stream when there is a dengue virus infec-
tion. The binding of the epitope or whole protein to the lm was
studied based on quartz-crystal microbalance (QCM) frequency
shis.
To date, there have been very few studies on molecular
imprinting of whole viruses as templates andmost of these were
on 2D virus imprints used in sensing technologies.14 Biosensors
were developed that can detect viruses by integrating molecular
imprinting and quartz-crystal microbalances (QCMs).15
Imprinted polymeric lms were produced using the so gel
stamping technique and were found to bind the tobacco mosaic
virus (TMV) target on the electrode of the QCM. Diﬀerent
polymers such as polyurethanes and polyacrylates were used as
the polymer matrix, and the stamping technique was further
applied to more viral strains such as human rhinovirus, foot
and mouth disease virus and the parapox ovis virus, a harmless
surrogate for smallpox virus. In addition to these 2D imprinting
methods, others have focused on using polymeric gels as bulk
imprinting matrices using whole viral templates.16 The
imprinted gels displayed enhanced TMV uptake compared to a
diﬀerently shaped non-target tobacco necrosis virus. Though
this method was successful in creating polymers having cavities
that mimicked the shape of TMV, the study was not extended to
the prevention of viral infections.
Miniemulsion polymerization is a technique that involves
the dispersion of monomers in a continuous phase with
application of high shear forces. A co-surfactant is added to
suppress diﬀusion processes occurring in the continuous phase
in order to create a stable emulsion with homogeneous sizes.
This technique produces a nearly 1 : 1 transfer of monomer
nanodroplets into regularly shaped polymerized beads as small
as 50 nm.17With excellent heat dispersal and consistent product
quality this polymerization technique is highly suited for large-
scale production. For molecular imprinting, miniemulsion
polymerization was studied for targets such as drugs,18 amino
acids19 and proteins,9 but there are no known reports on its
application to viruses.
At rst, we have successfully fabricated surface imprinted
nanoparticles using a one-stage miniemulsion polymerization,9
while dening an optimized condition for its eﬀective applica-
tion to protein imprinting.10 This surface imprinting approach
served to solve the limitations posed by the traditional bulk
imprinting methodology in addition to making it suitable for
large-scale commercial production. Following this, a two-stage
core–shell miniemulsion polymerization surface imprinting
approach was developed using immobilized templates7 and its
general applicability was illustrated for a whole class of protein
molecules.20 All of the imprinted polymeric nanoparticles dis-
played excellent template recognition, superior imprinting2032 | J. Mater. Chem. B, 2013, 1, 2031–2037eﬃciency, favorable adsorption kinetics and selectivity in an
aqueous medium for proteins. As viruses have an outer capsid
with abundant surface proteins, this molecular imprinting
technique was used to create complementary polymeric mimics
of these protein-based viral shells. In order to accomplish this, a
one-stage and a two-stage redox-initiated miniemulsion poly-
merization processes were employed and the imprinting
process was carried out by the addition of whole viral particles
into the polymerization system. Subsequently, the anti-viral
activity of imprinted polymers was investigated both in the
absence and presence of host cells. To the best of our knowl-
edge, this is the rst study on the application of imprinted
materials as anti-viral agents targeted at infectious disease
treatment. The novelty of this work lies in the unique combi-
nation of surface imprinting of whole viral templates using
miniemulsion polymerization producing imprinted polymers
that are applied as anti-virals in a model host–viral system.Results and discussion
A series of inhibition assays of viral infection were performed in
a model host–virus system in order to replicate real-time
infection conditions. For this proof of concept study, a simple
bacteriophage was used as the model virus as they are
increasingly being used as surrogates for human viruses.
Phages are viruses that infect bacteria and an fr bacteriophage
(ATCC 15767-B1) was chosen as the model virus in this
study. Fr is a small enteric phage that belongs to the family
Leviviridae and is specic to its bacterial host Escherichia coli
(ATCC 19853).21 The infective fr virion is icosahedral in
shape composed of a coat protein, a maturation (or A) protein
and a single-stranded RNA. The coat protein and other matu-
ration proteins assemble to form the phage of about 23 nm in
size. It has an isoelectric point ranging from 8.9 to 9 22 and thus
the virus has an overall positive charge in the naturally occur-
ring pH range of 6–8. Bacteriophages such as the fr phage have
been recently used as “indicator viruses” owing to their simi-
larity to many medically important human viruses such as
enteroviruses in terms of size, composition, structure and
morphology. In addition, the absence of replication in the
environment similar to mammalian viruses that do not repli-
cate outside the human body makes them an ideal human
surrogate virus in this work. The fr phages used in our studies
were prepared in-house (see Fig. S1 in the ESI†). For details on
the host and phage propagation, purication and phage
enumeration assay used, please refer Materials and methods
section in the ESI.†Virus surface imprinted nanoparticles (vMIPs)
A one-stage redox-initiated miniemulsion polymerization was
employed in the preparation of surface imprinted nano-
particles. The selectivity of any imprinted polymer is deter-
mined by the functional monomers used with methacrylate and
acrylic acid monomers being used previously for imprinting of
biomolecules through non-covalent assembly.23 In the rst
set of experiments, nanoparticles were prepared using aThis journal is ª The Royal Society of Chemistry 2013





















































































View Article Onlinehydrophobic cross-linker ethylene glycol dimethacrylate
(EGDMA) mixed with diﬀerent functional monomers with a
xed molar ratio of 1 : 4. Virus imprinted nanoparticles (vMIPs)
were obtained by the addition of the whole viral template virus
(fr phages) into the monomer phase prior to the polymerization
step. Non-imprinted particles (NIPs) were also prepared without
the addition of the template virus and were used as controls in
all the experiments. X-ray photoelectron spectroscopy (XPS) was
used to conrm the inclusion of the template during mini-
emulsion polymerization and template extraction by SDS/acetic
acid (see Results section in the ESI†). The one-stage mini-
emulsion polymerization system for virus surface imprinting is
illustrated in Fig. 1.Surface imprinted nanoparticles using immobilized virus
template (viMIP)
An alternative viral imprinting method, a two-stage mini-
emulsion polymerization, was also used to improve viral
recognition. In this strategy, the whole viral templates were
covalently immobilized onto support particles before the
surface imprinting was performed. The advantage of template
immobilization can be realized in cases where the template
molecules are not soluble in the imprinting polymerization
mixture and has previously been proven to be eﬀective for
imprinting protein molecules.7 Virus immobilized molecularly
imprinted polymeric nanoparticles (viMIPs) and the corre-
sponding non-imprinted particles (iNIPs) were prepared and
the results of the characterization studies have been discussed
in the Results section in the ESI.†Fig. 2 Virucidal eﬀect of nanoparticles on phage viability. Bars represent stan-
dard error. Statistical signiﬁcance was denoted by +/*. Student's t-test: *p < 0.01;
+p < 0.05 ( – virus imprinted particles; – non-imprinted particles).Anti-phage activity of imprinted particles
The eﬀect of the imprinted particles on phage viability was
studied. Equal volumes of phage solutions of 6300 pfu mL1
titer were aseptically mixed with imprinted and non-imprinted
particles prepared using both of the polymerization methods
above. Aer 24 h of mixing at 4 C, the phage concentration in
the supernatant was established by standard plaque assays as
described in the Experimental methods section. Controls con-
taining only phages were also subjected to the test. TheFig. 1 An illustration of virus surface imprinting via one-stage miniemulsion polym
This journal is ª The Royal Society of Chemistry 2013virucidal eﬀect was expressed in terms of Log Reduction Value
(LRV):
LRV ¼ log(CINITIAL)  log(CSUPERNATANT) (1)
where CINITIAL and CSUPERNATANT are the concentration of
viruses before and aer mixing with particles (pfu mL1).
Higher LRV signies a lower CSUPERNATANT value and hence a
greater virucidal eﬀect. It can be observed that the fr phages
were sensitive to all the particles prepared in this study.
However, maximum reduction in phage titers was obtained for
the imprinted nanoparticles as compared to their non-imprin-
ted counterparts. At an equal polymer dose of 0.01 g mL1, 1.16
and 1.46 times higher log reduction was obtained for the
vMIPMMA and vMIPMAA respectively in contrast to the corre-
sponding non-imprinted particles (Fig. 2).
The reason for this virucidal action was due to the adsorp-
tion of viruses during the mixing procedure and the diﬀerence
in anti-viral activity can be attributed to the imprinting eﬀect as
explained below. Aer imprinting and template removal, the
vMIPs contain template-specic imprinted cavities that exhibit
greater aﬃnity towards the template virus (fr phages). Hence,erization.
J. Mater. Chem. B, 2013, 1, 2031–2037 | 2033





















































































View Article Onlinewhen these polymeric nanoparticles come in close proximity to
the template viruses, preferential binding occurs on the particle
surface resulting in an overall reduction in virus viability. As
mentioned above, hydrophobic and electrostatic interactions
dominate the phage binding processes of vMIPMMA and
vMIPMAA respectively. On the other hand, the non-imprinted
particles have been prepared in the absence of the template and
hence any virus uptake by these particles would be via non-
specic adsorption. Additionally, the vMIPMAA displayed 28%
higher log reduction in phage titers than the vMIPMMA. This
diﬀerence could be attributed to the fact that a greater amount
of template molecules were imprinted during the synthesis of
MAA imprinted polymers (see ESI Table 1†).
The inuence of virus concentration and polymer dose on
the virucidal eﬀect of the imprinted particles using one-stage
miniemulsion polymerization was also investigated (Fig. 3).
Increase in polymer dose had an obvious positive inuence on
the virucidal activity due to higher viral adsorption by the
particles. On the other hand, at an equal polymer dose, a one
log increase in phage concentration resulted in 12% decrease in
LRV and hence viral loading on the vMIPs. It can thus be seen
that poly(MMA-co-EGDMA) and poly(MAA-co-EGDMA) virus
surface imprinted nanoparticles were successfully fabricated
using one-stage redox-initiated miniemulsion polymerization.
In addition, the vMIPMAA particles displayed a greater virucidal
eﬀect as compared to vMIPMMA particles due to favorable
hydrogen bond formation and electrostatic interactions
between the template phages and particles resulting in
increased recognition and specic binding in the aqueous
environment.
A more interesting and eﬀective result was observed with the
alternative viral imprinting method. At equal polymer doses of
0.01 g mL1, a maximum reduction in phage infectivity titers
was obtained for the viMIPs as compared to all the polymeric
particles (Fig. 2), with an LRV of 3.25 times higher for the viMIPs
than for the control particles. This signies that the two-stage
imprinting strategy not only improved the virucidal behavior
due to higher specic virus uptake of the viMIPs but also
eﬀectively diminished the non-specic viral binding by theFig. 3 Virucidal eﬀect of nanoparticles on phage viability at diﬀerent (a) phage conc
mL1. Statistical signiﬁcance was denoted by *. Student's t-test: p < 0.01 ( – vMIPM
2034 | J. Mater. Chem. B, 2013, 1, 2031–2037iNIPs, proving the successful creation of imprinted sites on the
viMIPs. Although there is no prior work on using imprinted
polymers as anti-viral therapies, these results are comparable to
anti-viral drug screening studies performed using phages as
model viruses.24,25
RNA phages such as MS2 or fr were found to be least
susceptible to natural anti-viral extracts compared to other
human surrogate viruses.26 Additionally, non-enveloped phages
like fr or MS2 belonging to the Leviviridae family have been
illustrated to be relatively more resistant to disinfection and
other treatment processes exhibiting higher survival rates than
human viruses such as enteroviruses.27 This implies that the
virucidal action of the imprinted particles on phages may not
represent the general viral population behavior and in fact the
anti-viral eﬀect of particles will be magnied when applied to
human viruses. In addition to hydrophobic interactions occur-
ring between the functional monomer (MMA) and template
virus, shape complementarity of the binding cavities was also
responsible for the superior recognition, adsorption ability and
virucidal activity of the viMIP. Even so, there may be concerns
over the suitability of using MMA as the functional monomer
instead of MAA during the second stage of polymerization,
because hydrophobic interactions are generally considered less
specic than other non-covalent interactions like ionic and
hydrogen bonds. However, its ease of applicability in aqueous
medium and its eﬀective application in imprinting of biomol-
ecules has been previously demonstrated.28,29 Although MAA
proved to be a better functional monomer for the one-stage
imprinting polymerization of free viral templates, the superior
anti-viral eﬀects of viMIPs indenitely prove that imprinting of
viruses is also possible exclusively based on hydrophobic
interactions.
The kinetics of virus adsorption by the MIPs needs to be
known if they are to be used as anti-viral agents, and therefore
the virucidal eﬀect of a single dose of imprinted and non-
imprinted particles on phage viability was determined over
time. Equal volumes of phage suspensions at a concentration of
6300 pfu mL1 were mixed with the particles for 3, 6, 22.5, and
24 h at 4 C. At each time point the phage concentration in theentrations; a: 6300 pfu mL1; b: 63000 pfu mL1 and (b) polymer doses; X: 0.005 g
AA; – NIPMAA).
This journal is ª The Royal Society of Chemistry 2013
Fig. 5 Antiviral eﬀect of particles in a host–virus system after a single polymer
dose. Diﬀerences between the imprinted and control samples were statistically
signiﬁcant. Single-factor ANOVA: p < 0.01 ( : vMIPMAA; : NIPMAA; :
viMIP; : iNIP; : phage infected bacteria without particles; – non-
infected bacteria without particles).





















































































View Article Onlinesupernatant was evaluated by standard plaque assays. Controls
without MIPs, containing only phages were similarly tested
(Fig. 4). Aer just 3 h of mixing with phages, higher LRV values
of 0.67 and 0.56 were observed for samples containing vMIPMAA
and viMIP respectively compared to their non-imprinted coun-
terparts. A maximum of 1.09 log reduction in phage concen-
tration was observed aer 6 h of mixing with viMIPs. There were
no signicant diﬀerences in the initial and supernatant
concentrations of the controls without MIPs indicating that the
reduction in phage titers was caused due to specic phage
adsorption by the imprinted particles. The virus imprinted
particles displayed fast and favorable phage titer reduction
kinetics reaching equilibrium within 3 h. The phage adsorption
by non-imprinted particles is non-specic resulting in a
signicantly lower LRV aer 24 h. Additionally, it was also
found that the viruses adsorbed by the imprinted particles lose
their ability to infect the host cells (see Adsorbed virus infectivity
study in the Results section in the ESI†).
Preventing viral infections using imprinted particles
Even though the virucidal eﬀects were successfully demon-
strated, these conditions do not replicate the actual viral
infection conditions. Therefore, a study on the antiviral activity
of imprinted polymeric nanoparticles in the presence of host
cells was conducted with a bacterial growth assay. Bacterial cells
were infected with phage suspensions of a multiplicity of
infection (MOI or ratio of viruses to cell numbers) of 1 and
treated with a single dose of vMIP or viMIP together with the
controls. The bacterial growth of these samples was monitored
and this concentration (expressed in log numbers) was
enumerated aer 4 and 8 h of infection (Fig. 5). Phage infected
bacteria incubated with imprinted particles displayed the
highest bacterial concentration and faster growth rates at all
time, as compared to those with and without non-imprinted
particles. At a single polymer dose of 0.01 g mL1 aer 4 h of
infection, a 0.59 and 1.08 log higher bacterial concentrations
compared to phage infected bacteria were observed for samples
containing vMIPMAA and viMIP respectively. Aer 8 h ofFig. 4 Kinetic study of polymer dose response. Diﬀerences between the
imprinted and control samples were statistically signiﬁcant. Student's t-test: p <
0.01 ( : vMIPMAA; : NIPMAA; : viMIP; : iNIP).
This journal is ª The Royal Society of Chemistry 2013infection, a 15% reduction of this higher concentration was
observed for the imprinted particles. In contrast, bacterial
growth with the non-imprinted particles was sluggish and dis-
played lower concentrations that were similar to the phage
infected bacterial control samples. It can also be observed that
for a single MIP dose, the virus infection was not completely
blocked by the imprinted particles when compared to the non-
infected controls.
As a subsequent measure, a booster dose of 20% of the initial
polymer concentration was applied to all test samples (see
Fig. S2 in the ESI†). However, no statistically signicant
improvement in bacterial growth was observed even with the
booster dose in all cases. Additionally, it was also found that the
imprinted particles do not have any positive or negative eﬀect
on the host cell viability (see Inuence of particles on bacterial
growth in theResults section in the ESI†).
The fr phages infect the host E. coli in a lytic cycle and at the
beginning of this infection, free phages, phages adsorbed on
host cells, phage infected bacteria and uninfected cells all
coexist together. Therefore, in a treatment cycle, the imprinted
particles can target the fraction of extra-cellular phages. Anti-
virals are currently classied based on the diﬀerent stages of
viral infection and the discovery of drugs that target the initial
stages prior to viral attachment and entry is an eﬀective thera-
peutic approach. There are very few reports on entry inhibitors
with only one approved for use, which targets the surface
envelope protein of HIV and prevents viral fusion.30 Instead of
attacking a single protein residue or receptor, our imprinting
process targets a larger portion of the viral protein shell thereby
increasing the specicity and probability of whole viral surface
recognition and adsorption by the imprinted particles.
Assuming that the infected hosts do not divide together with the
absence of multiple phage adsorption to a single infected host,
the signicant improvement in bacterial concentration in the
presence of imprinted particles would be due to a proportional
decrease in phage infectivity titers. As observed from theJ. Mater. Chem. B, 2013, 1, 2031–2037 | 2035





















































































View Article Onlinekinetics study, maximum phage adsorption occurred aer 3 h of
contact time between the imprinted particles and phages.
Hence the virus imprinted particles target and adsorb the
phages thereby preventing the phages from infecting the host E.
coli cells.
However, phage growth is a function of two important
parameters: latent period and burst size.31 Latent period is the
time from the beginning of the infection cycle until cell lysis,
and the number of phages produced per cell in a generation is
termed as the burst size. The RNA-phages such as the fr have
been reported to have a burst size ranging between 10 and 100
phages per cell with a latent period between 10 and 60 min.32
Therefore, any fraction of the phages not adsorbed by the
particles can infect the cells to produce, on average, 55 phages
per infected cell every 35 min thus rapidly increasing phage
titers in a short time period, as would happen in a standard
phage infection. As the percentage of non-infected colonies also
doubles each generation, the phage replication cycle will reach
an equilibrium once the bacteria approach the stationary phase.
Therefore, the signicantly higher percentage of non-infected
colonies and 28.5% improvement in growth rate aer 4 h of
infection in the presence of the imprinted particles was due to
the prevention of viral attachment and entry to the host cells.
Although a complete cure was not observed since the rate of
phage replication was much higher than the phage adsorption
rate by the imprinted particles, the results strongly demon-
strated the antiviral activity of the imprinted particles as well as
a signicant reduction of viral infection. This treatment eﬀect is
similar to common antiviral drugs and viral vaccines as any viral
treatment can only aid in reducing the severity of illness but
may not totally block or prevent viral infection.
This study represents a novel eﬀort on the use of molecularly
imprinted materials as anti-virals for disease treatment. It is
also the rst report on the application of miniemulsion poly-
merization to prepare nanoparticles having a specic surface
imprinted memory of viruses. Virus imprinted polymeric
nanoparticles were prepared using diﬀerent functional mono-
mers and surface imprinting strategies with fr phages employed
as a model virus. The imprinted polymeric particles prepared
were of sizes ranging from 40 nm to 570 nm for the one- to two-
stage imprinting method. In comparison to standard antiviral
drugs that target the viral protein residues, virus-infected cells
or viral infection routes, which can be rendered non-eﬀective by
mutations, we put forward that the imprinted particles that
target the whole virus shell would be an ideal antiviral agent for
eﬀective virus-capture and infection inhibition. In order to
prove this non-conventional anti-viral therapy, a series of phage
infectivity and infection inhibition assays were performed in the
absence and presence of host cells respectively. The imprinted
particles exerted greater virucidal action than the non-imprin-
ted particles when incubated with only the phages due to
interactions between the template phages and particles result-
ing in increased recognition, specic adsorption and virus
capture. The virus imprinted particles also displayed fast phage
titer reduction kinetics, reaching an equilibrium aer only 3 h
of contact time. Finally, a proof-of-concept study on the anti-
viral action of the imprinted particles in the presence of the host2036 | J. Mater. Chem. B, 2013, 1, 2031–2037cells showed that samples treated with imprinted particles had
signicantly higher bacterial growth rates and concentrations
when dosed with phages, proving that the imprinted particles
are able to signicantly reduce phage infection in E. coli.
Further characterization of captured virus viability together
with optimization of viral concentrations, the timing of polymer
doses, and host–virus ratio to maximize the antiviral activity of
the particles are needed to better elucidate the mechanism of
infection inhibition and ultimately testing with human viruses.
The simple design, instantaneous fabrication and ease of use of
the polymeric particles enable easy scale-up and large volume
production suitable for pharmaceutical applications. The viral
imprints may eventually be applied as antiviral agents in
topical, extracorporeal or combination treatment therapies
providing an economical solution to traditional antiviral strat-
egies or even as disinfecting agents in water treatment facilities.Experimental methods
Preparation of the virus surface imprinted nanoparticles
(vMIPs)
Miniemulsion polymerization was used for the virus imprinting
process as in our previous studies.9,10 Briey, the aqueous phase
was mixed with the oil phase and homogenized at 24 000 rpm
with a homogenizer (T25B, IKA Labortechnik, Germany) to
create a miniemulsion. The model virus fr phages were added
into the miniemulsion and mixed with a magnetic stirrer to
allow interaction between template and functional monomers.
The mixture was then diluted in a second aqueous phase and
polymerized for 24 h at 40 C (see Materials and methods
section in the ESI†).Preparation of surface imprinted nanoparticles using an
immobilized virus template (viMIP)
Core–shell surface imprinted particles were prepared following
the described method as in our previous work7 (for detailed
procedures, see Materials and methods section in the ESI†).
Briey, poly(MMA-co-EGDMA) support beads were synthesized
in a rst-stage core–shell miniemulsion polymerization.
Subsequently, aminolysis, aldehyde functionalization and virus
immobilization were performed on the support particles. A
second stage of miniemulsion polymerization was initiated to
form a polymeric shell over the virus-immobilized core parti-
cles. The template virus was extracted through base hydrolysis,
creating an outer imprinted shell having complementary
binding cavities specic to the template virus producing virus
immobilized molecularly imprinted polymers (viMIPs). The
corresponding non-imprinted polymers (NIP and iNIP) to the
above vMIP and viMIP respectively were prepared and washed
in a similar manner, except without the addition of the template
virus immobilization step. These particles served as control
samples in the characterization and adsorption studies.Anti-phage activity of imprinted particles
Equal volumes of phage solutions and polymeric nanoparticle
suspensions were mixed under aseptic conditions. The samplesThis journal is ª The Royal Society of Chemistry 2013





















































































View Article Onlinecontaining the phage–nanoparticle suspension were aﬃxed
onto a rotamix (RKVS, ATR Inc., Japan) and mixing was carried
out at an ambient temperature of 4 C. Positive control con-
sisted of phage solutions without particles. At diﬀerent time
points from the start, the samples were centrifuged (Universal
32R, Hettich Zentrifugen, Germany) at 9000 rpm and the
supernatant was titered by plaque assay to determine the
supernatant phage concentration. Similar experiments were
performed at diﬀerent polymer doses and phage concentrations
in order to study their inuence on phage infectivity. The test
was also carried out for the NIP and iNIP nanoparticles as
control experiments.Preventing viral infections using imprinted particles
The anti-viral activity of the virus imprinted nanoparticles
was studied in a model host–virus system. A xed concen-
tration of aerobically grown bacterial cells was inoculated
with phage suspensions in the presence of vMIP or viMIP. The
solutions were mixed thoroughly and incubated at 37 C and
300 rpm. Controls included phage-infected bacteria with and
without non-imprinted particles (NIP and iNIP) and non-
infected bacteria without particles. At diﬀerent time points,
samples were drawn to determine the bacterial concentration
established by colony counting on agar plates. The above
experiment was further repeated to study the toxicity of the
particles towards the host bacterium. The growth of non-
infected bacteria with and without particles was monitored
for 12 h at 37 C.Statistical analysis
Triplicate samples were used for each sample set. OriginPro 8.1
(OriginLab, Northampton, MA) was the graphing soware used.
Standard deviation calculations, Student's t-tests and one-way
analysis of variance (one way-ANOVA) were carried out using
Microso Excel (Seattle, WA) for statistical comparisons
between pairs of samples and multiple sample analysis.Acknowledgements
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